SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(McDonagh Theresa) "

Sökning: WFRF:(McDonagh Theresa)

  • Resultat 1-10 av 18
  • [1]2Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Kapelios, Chris J, et al. (författare)
  • Association between loop diuretic dose changes and outcomes in chronic heart failure : observations from the ESC-EORP Heart Failure Long-Term Registry.
  • 2020
  • Ingår i: European Journal of Heart Failure. - 1388-9842 .- 1879-0844. ; 22:8, s. 1424-1437
  • Tidskriftsartikel (refereegranskat)abstract
    • AIMS: Guidelines recommend down-titration of loop diuretics (LD) once euvolaemia is achieved. In outpatients with heart failure (HF), we investigated LD dose changes in daily cardiology practice, agreement with guideline recommendations, predictors of successful LD down-titration and association between dose changes and outcomes.METHODS AND RESULTS: We included 8130 HF patients from the ESC-EORP Heart Failure Long-Term Registry. Among patients who had dose decreased, successful decrease was defined as the decrease not followed by death, HF hospitalization, New York Heart Association class deterioration, or subsequent increase in LD dose. Mean age was 66 ± 13 years, 71% men, 62% HF with reduced ejection fraction, 19% HF with mid-range ejection fraction, 19% HF with preserved ejection fraction. Median [interquartile range (IQR)] LD dose was 40 (25-80) mg. LD dose was increased in 16%, decreased in 8.3% and unchanged in 76%. Median (IQR) follow-up was 372 (363-419) days. Diuretic dose increase (vs. no change) was associated with HF death [hazard ratio (HR) 1.53, 95% confidence interval (CI) 1.12-2.08; P = 0.008] and nominally with cardiovascular death (HR 1.25, 95% CI 0.96-1.63; P = 0.103). Decrease of diuretic dose (vs. no change) was associated with nominally lower HF (HR 0.59, 95% CI 0.33-1.07; P = 0.083) and cardiovascular mortality (HR 0.62, 95% CI 0.38-1.00; P = 0.052). Among patients who had LD dose decreased, systolic blood pressure [odds ratio (OR) 1.11 per 10 mmHg increase, 95% CI 1.01-1.22; P = 0.032], and absence of (i) sleep apnoea (OR 0.24, 95% CI 0.09-0.69; P = 0.008), (ii) peripheral congestion (OR 0.48, 95% CI 0.29-0.80; P = 0.005), and (iii) moderate/severe mitral regurgitation (OR 0.57, 95% CI 0.37-0.87; P = 0.008) were independently associated with successful decrease.CONCLUSION: Diuretic dose was unchanged in 76% and decreased in 8.3% of outpatients with chronic HF. LD dose increase was associated with worse outcomes, while the LD dose decrease group showed a trend for better outcomes compared with the no-change group. Higher systolic blood pressure, and absence of (i) sleep apnoea, (ii) peripheral congestion, and (iii) moderate/severe mitral regurgitation were independently associated with successful dose decrease.
  •  
2.
  • McDonagh, T. A., et al. (författare)
  • European Society of Cardiology Heart Failure Association Standards for delivering heart failure care
  • 2011
  • Ingår i: European Journal of Heart Failure. - : Oxford University Press. - 1388-9842. ; 13:3, s. 235-241
  • Tidskriftsartikel (refereegranskat)abstract
    • The management of heart failure (HF) is complex. As a consequence, most cardiology society guidelines now state that HF care should be delivered in a multiprofessional manner. The evidence base for this approach now means that the establishment of HF management programmes is a priority. This document aims to summarize the key elements which should be involved in, as well as some more desirable features which can improve the delivery of care in a HF management programme, while bearing in mind that the specifics of the service may vary from site to site. We envisage a situation whereby all patients have access to the best possible care, including improved access to palliative care services, informed by and responsive to advances in diagnosis management and treatment. The goal should be to provide a 'seamless' system of care across primary and hospital care so that the management of every patient is optimal, no matter where they begin or continue their health-care journey.
  •  
3.
  •  
4.
  •  
5.
  •  
6.
  •  
7.
  •  
8.
  • Elliott, Perry, et al. (författare)
  • Development, validation and implementation of biomarker testing in cardiovascular medicine state-of-the-art : Proceedings of the European Society of Cardiology - Cardiovascular Round Table.
  • 2020
  • Ingår i: Cardiovascular Research. - 0008-6363 .- 1755-3245.
  • Tidskriftsartikel (refereegranskat)abstract
    • Many biomarkers that could be used to assess ejection fraction, heart failure, or myocardial infarction fail to translate into clinical practice because they lack essential performance characteristics or fail to meet regulatory standards for approval. Despite their potential, new technologies have added to the complexities of successful translation into clinical practice. Biomarker discovery and implementation requires a standardised approach that includes: identification of a clinical need; identification of a valid surrogate biomarker; stepwise assay refinement, demonstration of superiority over current standard-of-care; development and understanding of a clinical pathway; and demonstration of real-world performance. Successful biomarkers should improve efficacy or safety of treatment, while being practical at a realistic cost. Everyone involved in cardiovascular healthcare, including researchers, clinicians, and industry partners, are important stakeholders in facilitating the development and implementation of biomarkers. This paper provides suggestions for a development pathway for new biomarkers, discusses regulatory issues and challenges, and suggestions for accelerating the pathway to improve patient outcomes. Real life examples of successful biomarkers-high sensitivity cardiac troponin (hs-cTn), T2* cardiovascular magnetic resonance (CMR) imaging, and echocardiography-are used to illustrate the value of a standardised development pathway in the translation of concepts into routine clinical practice.
  •  
9.
  •  
10.
  • Jaarsma, Tiny, et al. (författare)
  • Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology.
  • 2009
  • Ingår i: European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology. - : Oxford University Press. - 1388-9842 .- 1879-0844. ; 11:5, s. 433-43
  • Tidskriftsartikel (refereegranskat)abstract
    • Heart failure is a serious condition and equivalent to malignant disease in terms of symptom burden and mortality. At this moment only a comparatively small number of heart failure patients receive specialist palliative care. Heart failure patients may have generic palliative care needs, such as refractory multifaceted symptoms, communication and decision making issues and the requirement for family support. The Advanced Heart Failure Study Group of the Heart Failure Association of the European Society of Cardiology organized a workshop to address the issue of palliative care in heart failure to increase awareness of the need for palliative care. Additional objectives included improving the accessibility and quality of palliative care for heart failure patients and promoting the development of heart failure-orientated palliative care services across Europe. This document represents a synthesis of the presentations and discussion during the workshop and describes recommendations in the area of delivery of quality care to patients and families, education, treatment coordination, research and policy.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 18
  • [1]2Nästa
Typ av publikation
tidskriftsartikel (17)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (18)
Författare/redaktör
McDonagh, Theresa (16)
Kolh, Philippe (9)
Dean, Veronica (9)
Anker, Stefan D (9)
Ponikowski, Piotr (8)
Filippatos, Gerasimo ... (8)
visa fler...
Reiner, Željko (8)
Vahanian, Alec (8)
Sechtem, Udo (8)
Ceconi, Claudio (8)
Funck-Brentano, Chri ... (8)
Tendera, Michal (7)
Knuuti, Juhani (7)
Windecker, Stephan (7)
Widimsky, Petr (6)
Auricchio, Angelo (6)
Torbicki, Adam (5)
Lip, Gregory Y H (5)
Hasdai, David (5)
Baumgartner, Helmut (5)
Fagard, Robert (5)
Kirchhof, Paulus (5)
Deaton, Christi (5)
Atar, Dan (4)
Jaarsma, Tiny (4)
Hindricks, Gerhard (4)
Piepoli, Massimo F. (4)
Metra, Marco (4)
Gorenek, Bulent (4)
Collet, Jean-Philipp ... (3)
Agewall, Stefan (3)
Zamorano, Jose Luis (3)
Iung, Bernard (3)
Lancellotti, Patrizi ... (3)
Ruschitzka, Frank (3)
Voors, Adriaan A. (3)
Huber, Kurt (3)
Zannad, Faiez (3)
Camm, A. John (3)
Dickstein, Kenneth (3)
Blomström-Lundqvist, ... (3)
Merkely, Bela (3)
Le Heuzey, Jean-Yves (3)
Bax, Jeroen J (3)
Vardas, Panos E (3)
Goette, Andreas (3)
Heidbuchel, Hein (3)
Perrone Filardi, Pas ... (3)
Ernst, Sabine (3)
Savelieva, Irene (3)
visa färre...
Lärosäte
Uppsala universitet (9)
Linköpings universitet (6)
Göteborgs universitet (4)
Karolinska Institutet (2)
Lunds universitet (1)
Högskolan i Skövde (1)
visa fler...
Linnéuniversitetet (1)
visa färre...
Språk
Engelska (18)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (9)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy